Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
23 participants
INTERVENTIONAL
2020-10-01
2021-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Probiotic in Treatment of Adult Patients With Drug-resistant Epilepsy
NCT05160350
The Efficacy and Safety of Minocycline in the Treatment of Drug-resistant Epilepsy in NORSE Patients
NCT05958069
Study of Cannabidiol for Drug-Resistant Epilepsies
NCT03014440
Drug Resistant Epilepsy: Clinical and Genetic Study
NCT04166305
MiCrobiota-gut-brain Axis in Resistant Epilepsy
NCT07010445
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ciprofloxacin
Ciprofloxacin Oral Product
The first stool sample will be taken before treatment and the second one will be taken in day 5 to 7 after treatment initiation. Treatment includes ciprofloxacin tablet 500mg twice a day for 5 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ciprofloxacin Oral Product
The first stool sample will be taken before treatment and the second one will be taken in day 5 to 7 after treatment initiation. Treatment includes ciprofloxacin tablet 500mg twice a day for 5 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acceptance of patients or his/her guardian (Signing informed consent)
Exclusion Criteria
* History of tendon, renal, hepatic or cerebrovascular disease, organ transplantation or myasthenia gravis
* Usage of medications with interaction to ciprofloxacin
* No reliable contraception
* Pregnancy or breastfeeding
* Being under treatment with corticosteroid
* Usage of antibiotics in recent 2 months or need to use it during the study
* Patients who are candidate for epilepsy surgery or other nonmedical treatments
* Change in anti-seizure medications (ASMs) during recent month
* Patients who will need changes in ASMs dose during study
16 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mazandaran University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nasim Tabrizi
Associate professor of neurology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bu Ali Sina hospital
Sari, Mazandaran, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5210
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.